WHO Pharmaceuticals Newsletter 2004, No. 01
(2004; 17 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentANTIEPILEPTICS - ADR update from Australia
View the documentBOTULINUM TOXIN TYPE A - Place in therapy not clearly defined
View the documentCELECOXIB/ROFECOXIB - Acute temporary visual impairment
View the documentDACLIZUMAB - Increased mortality in cardiac transplant patients
View the documentFLUTICASONE - Update on adrenal insufficiency reports
View the documentINTERFERON BETA - Safety information about risk of liver injury
View the documentMETHADONE - Risk of QT prolongation
View the documentMETHOTREXATE - Update on pulmonary effects
View the documentMIRTAZAPINE - ADR update from Australia
View the documentMORPHINE - Accidental overdose of concentrated oral solutions
View the documentNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) - Postpartum administration may cause hypertension
View the documentPERGOLIDE - Danger of falling asleep during daily activities
View the documentPYRAZINAMIDE & RIFAMPICIN - Serious liver injury with combined use in latent tuberculosis
View the documentSIBUTRAMINE - ADR update
View the documentTOPIRAMATE - Warning about metabolic acidosis
View the documentWARFARIN - Interaction with cranberry juice
Open this folder and view contentsDRUGS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

WARFARIN - Interaction with cranberry juice

UK. The Committee on Safety of Medicines (CSM) has drawn attention to a possible interaction between warfarin and cranberry juice. Since 1999 the CSM has received five reports of a possible interaction between warfarin and cranberry juice leading to changes in the International Normalized Ratio (INR) values. One case was fatal and involved a man whose INR increased to more than 50 six weeks after he started drinking cranberry juice; he died of gastrointestinal and pericardial haemorrhage. Two other patients experienced increased INRs when taking cranberry juice; one patient stabilised following a reduction in warfarin dosage and the other's INR normalised after cranberry juice was stopped. A fourth patient experienced an unstable INR, and a decreased INR was reported in another patient. The CSM notes that the interaction is biologically plausible through inhibition of cytochrome P450 by flavonoids in cranberry juice and suggest that, until the possible interaction is investigated further, it would be prudent for patients taking warfarin to limit or avoid drinking cranberry juice.

Reference:
Current Problems in Pharmacovigilance, September 2003. Available from URL: http://www.mca.gov.uk

 

to previous section to next section
 

Last updated: May 3, 2013